Livzon Pharmaceutical Group Inc.
000513
Rank in Stocks
#4689
Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and... Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturing and commercialization. The company's operations encompass a diverse range of finished drug products, active pharmaceutical ingredients (APIs), and chemical intermediates, primarily serving the Chinese market while also engaging in international exports. Its pharmaceutical portfolio includes treatments such as Ilaprazole enteric coated tablets for duodenal ulcers and reflux esophagitis, Laprazole sodium injection for managing peptic ulcer bleeding, Leuprorelin Acetate Microspheres for injection, and Urofollitropin injection for anovulation and fertility support. Livzon also produces Perospirone Hydrochloride for schizophrenia, Anti-viral Granules targeting upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, spontaneous sweating, and vertigo, and provides supportive care for lung and stomach cancer patients. Beyond therapeutic drugs, Livzon Pharmaceutical Group develops and distributes a variety of diagnostic reagents. These include kits for detecting IgM/IgG antibodies to coronavirus, nucleic acid tests for human immunodeficiency virus type 1, antinuclear antibody test kits, interferon-gamma release assay kits, and rapid tests for mycoplasma pneumoniae IgM antibodies. The company's extensive offerings further extend to biochemical drugs, microbiological preparations, biologics, traditional Chinese medicine formulations, pharmaceutical raw materials, and antibiotics.
Share Price
$3.90
Market Cap
$3.17B
Change (1 day)
-3.49%
Change (1 year)
-25.88%
Country
CN
Trade Livzon Pharmaceutical Group Inc. (000513)
Category
Healthcare
Revenue for Livzon Pharmaceutical Group Inc. (000513)
Revenue in Jun 2026 TTM: $1.61B
According to Livzon Pharmaceutical Group Inc. latest financial reports the company's current revenue (TTM) is $1.61B. In 2024 the company made a revenue of $1.62B a decrease compared to the revenue in the year 2023 that was $1.76B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Livzon Pharmaceutical Group Inc. from 2001 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $1.61B | -5.45% |
| 2025 | $1.70B | 5.18% |
| 2024 | $1.62B | -7.84% |
| 2023 | $1.76B | -4.09% |
| 2022 | $1.83B | -3.54% |
| 2021 | $1.90B | 17.86% |
| 2020 | $1.61B | 19.49% |
| 2019 | $1.35B | 4.63% |
| 2018 | $1.29B | -1.76% |
| 2017 | $1.31B | 18.97% |
| 2016 | $1.10B | 8.10% |
| 2015 | $1.02B | 13.90% |
| 2014 | $895.10M | 17.55% |
| 2013 | $761.43M | 20.40% |
| 2012 | $632.40M | 26.05% |
| 2011 | $501.72M | 21.45% |
| 2010 | $413.11M | 8.65% |
| 2009 | $380.22M | 26.03% |
| 2008 | $301.69M | 26.02% |
| 2007 | $239.41M | 17.50% |
| 2006 | $203.75M | 1.14% |
| 2005 | $201.46M | 7.23% |
| 2004 | $187.88M | -14.19% |
| 2003 | $218.94M | 13.17% |
| 2002 | $193.46M | 14.69% |
| 2001 | $168.68M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $23.54B | 1,362.30% |
DE
|
|
| $23.73B | 1,374.71% |
DE
|
|
| $29.24B | 1,716.72% |
JP
|
|
| $5.85B | 263.40% |
CH
|
|
| $6.34B | 294.06% |
IN
|
